CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 506 enrolled
Drug / intervention
Varenicline +2 moredrug
Likely dose
Varenicline 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00935818
NCT00935818Phase 3Completed
CompareCT.gov

Combination Therapy With Varenicline and Bupropion for Smoking Cessation

Mayo Clinic·interventional·Posted Jul 9, 2009·Updated May 9, 2014

In Brief

A Phase 3 clinical trial evaluating Varenicline, placebo, and 1 other intervention for Smoking. Completed, enrolled 506 participants across 3 sites.

Detailed Summary

This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), University of Minnesota

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 9, 2009
Enrollment StartSep 1, 2009
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.0 years ago

Interventions

Vareniclinedrug

varenicline - 1 mg bid for 12 weeks

placebodrug

placebo for 12 weeks

bupropion SRdrug

bupropion sr - 150 mg bid for 12 weeks